Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine Acetyltransferase 6 (KAT6) refers to a family of histone acetyltransferases, including KAT6A and KAT6B, that play crucial roles in chromatin remodeling and gene regulation. These enzymes are part of the MYST family of acetyltransferases and are highly conserved across species. They regulate transcriptional activation by modifying chromatin accessibility, are essential for proper development of hematopoietic stem cells as well as neural stem cells, and are involved in cell cycle progression, mitosis, DNA damage repair, metabolism, and immune response. Mutations in KAT6A cause Arboleda-Tham syndrome (ARTHS). Both upregulation and downregulation have been linked to cancer formation/progression. Recent studies show KAT6A orchestrates metabolic reprogramming in CD4+ T cells via epigenetic regulation. Small-molecule inhibitors targeting KAT6A show therapeutic potential against autoimmunity.
Targeted inhibition of KAT6A alters histone acetylation and modulates gene expression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine Acetyltransferase 6 (None).